EGFR and non-small cell lung carcinoma: Furthermore, while ICIs have transformed NSCLC treatment, their role in EGFR‐mutant NSCLC post‐TKI resistance is controversial, with conflicting data on the impact of PD‐L1 expression and T790M status [13].